SGMO insider trading
NasdaqCM HealthcareSANGAMO THERAPEUTICS, INC: insider trade history from SEC Form 4 filings.
About SANGAMO THERAPEUTICS, INC
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Company website: www.sangamo.com
SGMO insider activity at a glance
FilingIQ tracks 745 insider transactions for SGMO in filings since Jan 6, 2015. The most recent transaction is dated May 25, 2026.
Across the full history, 54 open-market purchases
and 230 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SGMO insider trades is 48.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SGMO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SGMO?
- FilingIQ tracks 745 Form 4 insider transactions for SGMO (SANGAMO THERAPEUTICS, INC), covering filings from Jan 6, 2015 onwards. 0 of those are dated within the last 90 days.
- Are SGMO insiders net buyers or net sellers?
- Across the full Form 4 history for SGMO, 54 transactions (7%) were open-market purchases and 230 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SGMO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is SGMO in?
- SANGAMO THERAPEUTICS, INC (SGMO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $145.59M.
Methodology & sources
Every SGMO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.